TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
OncoSil Medical Ltd ( (AU:OSL) ) just unveiled an update.
OncoSil Medical Limited has announced the appointment of Dr. Thomas Duthy as the new Non-Executive Chairman, effective 1 October 2025. Dr. Duthy, who brings over 20 years of experience in healthcare and technology, replaces Mr. Doug Cubbin, who will transition to a Non-Executive Director role. This strategic change is expected to support OncoSil’s growth in existing and new markets, as well as enhance clinical data generation to boost clinician adoption and market access. The announcement reflects OncoSil’s ongoing commitment to advancing its OncoSil™ device and achieving key milestones for its availability in targeted regions.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a medical device company that specializes in localized treatments for patients with unresectable locally advanced pancreatic cancer. The company’s primary product, the OncoSil™ device, aims to provide a valuable treatment option that increases patient survival without the side effects typically associated with systemic chemotherapy. OncoSil Medical focuses on expanding its market presence in key regions such as the US, EU, and the Middle East.
Average Trading Volume: 41,049
Technical Sentiment Signal: Sell
Current Market Cap: A$22.78M
For detailed information about OSL stock, go to TipRanks’ Stock Analysis page.